Innovative Discovery Solutions
Our Target
IBL aims at offering more efficient systemic treatments for cancers, with reasonable R&D cost through Bio-pharmaceuticals-based drug discovery and providing oncology research services.
Experience the Difference
Chemically Synthesizable biopharmaceuticals, as an emerging approach, in onco-indications can reduce the dependency on costly drugs (e.g biologics) that still have significant limitations. With its more attractive developmental (faster development time and lower cost of manufacturability) and pharmacological characteristics over small molecules and large biologics including less resistance and toxicities, and covering more diverse targets, mini proteins carry a great promise to unmet medical needs. This new approach is the heart of our research platforms.
Our Services
Out-licensing Drug Candidates
Collabration between Drug Discovery & Academia
Out-licensing Drug Candidates
We discover anticancer drug candidates. Our process begins with target identification, followed by proof of principle and proof of concept studies, culminating in the development and patenting of novel compounds. These patents are then made available for licensing to pharmaceutical companies for further development, regulatory approval,
We discover anticancer drug candidates. Our process begins with target identification, followed by proof of principle and proof of concept studies, culminating in the development and patenting of novel compounds. These patents are then made available for licensing to pharmaceutical companies for further development, regulatory approval, and commercialization. We have a particular focus on immune-oncology and agents targeting blood cancers, where we see significant unmet medical needs and promising therapeutic opportunities.
Research Services
Collabration between Drug Discovery & Academia
Out-licensing Drug Candidates
Our Discovery and Development Services business offers a broad range of drug discovery capabilities to support pharmaceutical and biotech clients. Based on input about target disease areas, we propose potential biological targets, validate them using in vitro and in vivo methods, and identify the most suitable candidates for further deve
Our Discovery and Development Services business offers a broad range of drug discovery capabilities to support pharmaceutical and biotech clients. Based on input about target disease areas, we propose potential biological targets, validate them using in vitro and in vivo methods, and identify the most suitable candidates for further development.
Our integrated approach includes target validation, hit identification, and early-stage screening, ensuring efficient progression from concept to lead discovery. We collaborate closely with our clients to align scientific strategies with therapeutic goals, helping accelerate the path to novel, high-impact drug candidates.
Collabration between Drug Discovery & Academia
Collabration between Drug Discovery & Academia
Collabration between Drug Discovery & Academia
The synergy of capabilities across the diverse organizations within the drug discovery ecosystem is essential to accelerating innovation. Collaboration among academic institutions, biotech companies, CROs, and pharmaceutical firms allows for the integration of complementary strengths—from target discovery and medicinal chemistry to bioin
The synergy of capabilities across the diverse organizations within the drug discovery ecosystem is essential to accelerating innovation. Collaboration among academic institutions, biotech companies, CROs, and pharmaceutical firms allows for the integration of complementary strengths—from target discovery and medicinal chemistry to bioinformatics and translational research. By combining these resources and expertise, we can streamline the traditionally slow and complex discovery process, reduce development risks, and deliver more effective and innovative therapies to patients in need.